Weight Loss & Metabolic / side effects and safety / Last reviewed 2026-04-04

Peptide YY Side Effects: Safety Signals and Warnings

Peptide YY safety concerns are compound-specific. The main listed side effects are Nausea (dose-limiting), Abdominal discomfort, and Reduced gastric motility. The main warning signals are Native peptide has very short half-life requiring continuous infusion, Nausea is a significant dose-limiting side effect, and Modified analogs are still in early clinical development.

Read the full Peptide YY guide Browse answer pages

Direct Answer

Peptide YY has Phase 1 human data confirming its satiety effects, but intranasal and injectable formulations have faced tolerability challenges (nausea) that have stalled clinical development. The gut-brain satiety axis it engages is mechanistically important. At this stage, PYY is a useful research tool for understanding appetite regulation rather than a viable weight-loss protocol compound.

Evidence grade
Level C
Research status
Phase 1
Category
Weight Loss & Metabolic
Best for
Gut-brain satiety axis research, appetite regulation mechanistic studies

Reported Side Effects

Warnings

Known or Plausible Interactions

Regulatory Context

Not FDA approved. Investigational. Native PYY available as a research peptide.

Evidence Snapshot

Evidence gradeLevel C
Research statusPhase 1
Best supported outcomesGastric Motility Reduction (Level B), Appetite Suppression (Level C), and Nausea (Level C)
Primary citation count2
Last reviewed2026-04-04

Related Guides

How to Cite This Page

ExaminePeptides. "Peptide YY Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/peptide-yy-side-effects-safety/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.